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INTRODUCTION 
 Ulcerative colitis (UC)  is  a chronic  inflammatory  disease  of the 
bowel, characterized by multiple  relapses & remission ,which leads to 
significant morbidity and health care cost and is also challenging to the 
treating gastroenterologist. 
 All chronic  diarrhoea  and rectal bleeding  during the year 1960 s  
were diagnosed as amoebic colitis or infective diarrhoea (1). Ulcerative 
colitis in India was first reported by Tandon and Chuttani et al (2). 
Various studies from India  as well as from south India  cites the 
increasing trends in  ulcerative colitis (3). 
 UC affects the mucosal layer of the colon and produces multiple 
ulcerations, diffuse inflammation and desquamation of the colonic 
epithelium. The etiology of UC is unknown; however, genetic,  
immunologic, and environmental  factors has a role in the pathogenesis of 
UC. The disease had a bimodal  distribution. Both young adults & elderly 
individuals are at risk for developing  this disorder. 
 The clinical presentations  in UC varies  , in severity, extent of 
disease,  presence of extraintestinal manifestations & response to therapy.  
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It was found that  9% have severe, 71% have moderate & 20% of patients 
with  mild disease activity at the time of presentation. 
 Diagnosis of UC is based on clinical, endoscopic and histo 
pathological findings.  Mucosal assessment   by colonoscopy is the best  
option in the diagnosis of ulcerative colitis . Newer diagnostic tools like 
chromoendoscopy ,NBI ,EUS  have a definite  role in the management of 
UC (4). 
 Severity of the disease is determined by assessing clinical 
symptoms, elevation in  ESR or CRP & by  fecal calprotectin. Dysplasia, 
colorectal malignancy, fulminant colitis were some of the feared 
complications of UC. 
 Response to therapy varies from patient  to patient. Treatment is to 
prevent complications and to provide a better quality of life. Mucosal 
healing  is the goal of therapy since it  is associated with a  decrease in 
colectomy  rates and other complications like dysplasia and decrease in  
the incidence of relapse and use of corticosteroids. 
 The pattern of mucosal healing varies  with different drugs  used in 
UC. Various studies provides insight into the value of achieving mucosal 
healing (5). 
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 Until recently, limited data  from India  is available about mucosal 
healing with various drugs in the management  of UC.  However, with the 
recent development of Multi-Matrix System (MMX) mesalamine, there 
are mucosal healing data from trials in UC (6). 
 Therefore the present study has been undertaken to asses the 
correlation  of  clinical  disease  activity with  that of endoscopic  activity 
in UC. 
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REVIEW OF LITERATURE 
 DR. Samuel Wilks  first described Ulcerative colitis   as idiopathic 
colitis and found that this disease is different from bacillary dysentery  
(7). In India UC was first reported by Tandon and Chuttani et al. 
EPIDEMIOLOGY 
 UC is one of the most prevalent gastrointestinal diseases (8). The 
prevalence   of UC ranges from 37 - 246 /100,000 persons (9). It is  a 
common disease in most of the industrialized countries in the world. The 
highest incidence is reported from Scandinavia  and Scotland  and then 
from England and North America (10). It was thought to be uncommon in 
the developing countries but there is an increasing  incidence & 
prevalence of UC in Hispanics and Asians &  they are more likely to have 
UC than Chrons disease (11). UC has a bimodal age distributation, 
primarily  in the third decade & again  in the 7th decade. Breast feeding, 
smoking and appendisectomy  appears  to have a protective role against 
UC (12,13). 
INDIAN SCENARIO 
 A  recent study from Indian sub continent found that   the  
incidence of UC  was 6.02/100000 / yr  &  a prevalence of 44.3/100000  
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population (14). Another  prevalence study from Singapore revealed  that 
the prevalence of UC was three times higher in Indians  when compared  
with that of the Chinese (15) .In another report  from UK  in  migrant 
South Asian group ,a higher prevalence  of UC was noted  in  this group 
than in  the Europeans(16). 
PATHOPHYSIOLOGY 
 The  interaction of genetic, environmental and immune factors play 
a role in the development of UC. Genetic factors were well demonstrated 
in twin studies. Genome-wide association studies showed that  IL23R, 
HLA-DR1  & major histocompatibility complex (MHC) class II  were 
associated  with UC (17,18). Failure  in the immune  tolerance leads to 
dysfunction of epithelial barrier function  & activate  immune system to 
secrete various cytokines and chemokines resulting in inflammation. 
 Environmental factors like mycobacterial infection, dysbiosis (19)  
of  intestinal microflora, diet like wheat, maize, cow milk were postulated 
to contribute to UC. Breast feeding, cigarette smoking and 
appendisectomy  are strong negative predictors of UC. 
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 Humoral and cellular immunity  has a role in the pathogenesis of 
UC. Immune dysregulation  is the likely factor.60 - 85% 0f UC patients 
have auto antibodies. 
 Psychogenic  factors  also has a role  in the pathogenesis of UC. 
PATHOLOGY 
 The disease starts from rectum and extends proximally with 
involvement of the mucosa in a continous and symmetrical manner but 
transmural involvement is rare. This feature differentiates UC from 
crohns disease. But in patients treated with enemas rectal sparing is seen. 
Periappendiceal involvement is another finding in UC. 
DISTRIBUTION 
 In UC, inflammation begins above the anorectum  and extends  
above in a diffuse  manner. When inflammation is restricted to 
The rectum                                      -  proctitis 
From  rectum  to  splenic flexure    -  left-sided colitis 
Beyond the splenic flexure             -  extensive colitis 
The entire colon                              -  pancolitis. 
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MACROSCOPY 
 In mild disease the  mucosa becomes hyperaemic.  Edema and 
granularity  are other features. When   it becomes severe, it progress to 
hemorrhagic  lesions with  ulcers which   increase in size & involve  the 
lamina propria. Recurrent, relapses  results in epithelial regeneration & 
leads to pseudopolyps . In  chronic disease, mucosa  become  atrophy  & 
have no specific  feature .It is characterised by shortening  & narrowing 
of the colon & also results in acute dilatation of the colon. 
MICROSCOPY 
 In early stage of the disease edema, congestion ,acute inflammatory 
cell infiltration  occurs. Cryptitis, crypt abscesses, goblet cell  mucin 
depletion, mucopus are other features of UC. In  chronic disease  
distortion of  architecture of the crypt occurs , atrophy of crypts, increase  
in the space between crypts, irregular epithelial mucosa,  basal aggregates 
of lymphoid cells   &  an infiltration  of  chronic inflammatory  cells are 
seen. The severity of inflammation in histology  will not correlate  well 
with clinical activity in  UC. (20) 
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THE  DISTINCTION OF UC FROM CROHNS DISEASE 
 Inflammatory change in the terminal ileum (‘‘backwash ileitis’’), 
involvement of the ileum or proximal gastrointestinal tract distinguishes 
UC from Crohn’s disease. The inflammation in ulcerative colitis is 
continuous and mucosal-based, rarely extending beyond the most 
superficial layers of the submucosa. The inflammation in Crohn’s disease 
is almost always patchy, and importantly, it is transmural and aggregated.  
The aggregate may be lymphoid follicles, or in a minority of cases,  it is 
granulomatous. 
NATURAL HISTORY 
 UC is characterized by periods of remission and relapse.  
A population-based cohort study revealed that , at the time of 
presentation, 9% had severe disease, 71% & 20% had moderate and mild 
disease respectively.  When they were  followed at 3 to 7 years  after 
initial diagnosis,  they found that 25% were in remission, continuous 
disease activity was seen in 18% and intermittent relapses in 57%. At  25 
years of follow-up, 90% had an intermittent course (21). The annual risk 
of relapse after  remission for 1 year was estimated to  be 20%. 
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CLINICAL PRESENTATION 
 Depends upon the anatomic location and severity of  disease  the 
clinical symptoms varies. Rectal bleeding is the commonest finding   
& may be  massive, or associated with expulsion  of mucopus. Diarrhoea   
is  related to decreased rectal compliance. Tenesmus, urgency are other 
features. Constipation & vague pain abdomen can also occur. Patients can 
have constitutional symptoms, like fever, fatigability, joint pain, and loss 
of weight. 
 Proctitis is characterised by the  presence of  inflammation 
confined to the distal 15 cms of rectum .It  is  most commonly seen, and 
usually the mildest  form of ulcerative colitis; constituting   about 25% to 
30% of cases .Patients with proctitis  have bleeding per rectum, urgency, 
and  sometimes constipation, because of late transit of fecal matter in the  
proximal colon. Other features like fever and other constitutional 
symptoms  are uncommon. 
 Procto sigmoiditis and  left sided colitis, accounts  for about fourty 
percent of UC cases. Patients can have either constipation or diarrhea 
associated with tenesmus, and  bleeding per rectum. In due course. It  can 
progress proximally  or  retract  to the distal colon. 
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 Left sided colitis is characterised by inflammation  upto the splenic 
flexure. 
 Extensive colitis and pancolitis have inflammation in the transverse  
colon  and  right colon. Patients presents  with loose stools  with  bleeding 
per rectum, urgency  and  tenesmus. Abdominal pain may be  localized  
or diffuse. 
 Toxic megacolon is the  severe form of UC, characterised by 
inflammation involving the superficial mucosa  and also into the 
submucosa  & muscule  layers. Fever, cramps, distention and  rebound 
tenderness are other features. 
EXTRAINTESTINAL MANIFESTATIONS 
 The commonest extraintestinal finding in  IBD is arthritis. 
Involvement of the skin,  eyes, mouth, joints & liver can occur. It can 
occur even  prior, during  or after  exacerbations of  intestinal   
disease (22). Peripheral arthropathy,  cutaneous  lesion & eye 
involvement were associated with severity of the disease. 
DIAGNOSIS 
 Clinical findings, blood ,stool analysis  & endoscopy in 
combination helps  in the diagnosis of IBD and also  to differentiate 
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ulcerative colitis from  crohns disease  as well as  to exclude other 
diseases. Colonoscopy can define the distribution, severity, and disease 
activity and also to  evaluate the response to  therapy ,to determine  the 
course of medical and surgical management. Multiple biopsies  are taken, 
at least two from the terminal ileum,  cecum,  ascending, transverse 
descending  and  sigmoid colon, and  also from  the rectum even if the 
mucosa appears normal. In long standing disease  colonoscopy plays an 
integral part  in dysplasia and colorectal cancer surveillance (23). 
 Narrow band imaging (NBI), chromoendoscopy can be used to 
improve the yield from mucosal biopsies (24). Even then in  4% to 6% of 
IBD, it is difficult  to differentiate  UC and CD and it is termed as   
IBD-unclassified (IBDU) (25). 
ASSESSMENT OF DISEASE EXTENT AND SEVERITY 
 Multiple clinical and endoscopic scoring methods are there to 
classify the severity of UC. The simplest clinical scoring system, is based 
on stool frequency, presence of fever, tachycardia, anemia, & elevated 
ESR(26). 
  12
Truelove and Witts Classification of the Severity of UC 
Mild 
  <4 stools/day, with or without only small amounts of blood 
  No fever 
  No tachycardia 
  Mild anemia 
  ESR < 30 mm/hr 
 
Moderate 
Intermediate between mild & severe 
Severe 
  >6 stools/day, with blood 
  Fever > 37.5 C 
  Heart rate > 90 beats/min 
  Anemia with Hb level < 75% of normal
  ESR > 30 mm/hr 
 
 
 Other scoring systems were the Baron score, Mayo score, Powell-
Tuck, Rachmilewitz  endoscopic index, and the UC Disease Activity 
Index (27-29).  Most of the scoring  system are similar in their description 
of inactive, mild, moderate   & severe UC. 
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ENDOSCOPIC ASSESMENT OF DISEASE  ACTIVITY IN UC 
 
 
 
 
 
 
SEROLOGICAL MARKERS 
 Perinuclear antineutrophil antibody (pANCA) is positive in  
60-70% patients with  UC. Combination of positive  pANCA & negative 
anti–Saccharomyces cerevisiae antibody (ASCA) had a sensitivity, 
specificity and  positive predicitive value of 57%, 97% & 92.5% 
respectievely. Elevated  ESR, CRP also indicates severe disease. 
Endoscopic Assessment 
0 Normal 
1 vascular pattern is lost 
2 Granularity, non friable 
3 Friable  on touch 
4 Spontaneous bleeding & ulceration
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DIFFERENTIAL DIAGNOSIS 
 A  lot  of inflammatory & non inflammatory conditions  can mimic   
UC. They are Cronhs colitis, Infective colitis, Ischemic colitis, Amoebic 
colitis, Microscopic colitis and Pseudomembranous colitis. 
WHAT IS MUCOSAL HEALING 
 In UC, IBD task force defined  mucosal healing as the absence of 
friable mucosa, blood or erosions  &  absence of ulcers in all visualized  
sites of colonic  mucosa (30). This is the endpoint for assessing disease 
activity. A population-based cohort  study from Norway revealed that  the 
presence of healing  of mucosa 1 year following the  diagnosis was 
significantly associated with a reduced need for colectomy at 5 years and 
reduced need for corticosteroids. 
TREATMENT 
 The  goals of treatment  are  control of symptoms, induction of 
remission, healing of endoscopic lesions, and prevention of 
complications. 
 Current management of UC has 3 main approaches: lifestyle 
modifications, medical therapy, and surgery. In mild to moderate disease  
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5-aminosalicylates (5-ASA) is still considered to be the first-line of  
treatment for induction & maintenance of remission (31). Oral 
aminosalicylates are useful in both proximal & distal colitis. Topical 
agents are effective  in distal colitis. 40% and 80%  clinical response  is 
seen  with  sulfasalazine or its alternate  forms in mild-to-moderate  
ulcerative colitis. The response rate  varies between clinical trials  due  to 
different  patient  groups  &  end-point  in the response. 
 In moderate to severe disease & in  those  who have no response 
for first-line 5-ASA therapy, corticosteroids are used for induction. Oral 
corticosteroids are not recommended for maintaining remission in 
ulcerative colitis. With severe disease, IV corticosteroid is indicated. 
Lack of improvement in 7 to 10 days is defined as failure of medical 
therapy and  is an indication for proctocolectomy (32). 
 Immunomodulators consist of thiopurine derivatives such as  
6-mercaptopurine and azathioprine  and methotrexate  and cyclosporine. 
 They are used in steroid-dependent  or  in 5-ASA refractory UC. 
Cyclosporine is used in the treatment of severe, steroid-refractory UC 
patients who face impending colectomy. 
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BIOLOGICALS 
 Infliximab (Remicade) is a chimeric, tumor necrosis factor 
monoclonal antibody, approved  by the FDA  both for  induction   
& maintenance of remission  in severe disease. It is also indicated for the 
treatment of extraintestinal manifestations of IBD, including ankylosing 
spondylitis, pyoderma gangrenosum, and chronic uveitis (33). Patients 
are  started treatment  with an induction dose of  five mg/kg intravenously 
at weeks zero, two, and six, then  with maintenance infusions every  
8 weeks. In partial responders, the dose can be raised  to 10 mg/kg. 
 The efficacy of infliximab therapy in adults with UC was evaluated 
in the, double-blind, placebo-controlled RCT termed Active Ulcerative 
Colitis Trial 1 and 2 (ACT-1 and ACT-2) (34). Thus, treatment with 
infliximab is helpful in   inducing    response in  patients with moderate-
to-severe active UC and also maintains a response if treatment is 
continued at 8-week intervals after the induction period. 
 Adaluzimab is not approved for treatment of UC. However,  
open-label trials showed ADA  is  useful  in induction  &  maintenance of  
remission in active UC in patients intolerant  or refractory to standard 
therapy (35). In the recent  ULTRA 2 study ADA was used in assessing 
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the efficacy of induction and maintenance of clinical remission in patients 
with moderate-to-severe UC. 
 Natalizumab is a humanized IgG4 monoclonal antibody against 
lymphocyte adhesion molecules, α4 integrins currently is approved for 
treating patients  with  Crohn's disease as a second line therapy; but  its 
use in UC is now under  evaluation. 
 Other new anti-adhesion molecule is MLN-02 ( LDP-02),  
a humanized IgG1 monoclonal antibody to α4β7 integrin. In a phase 2 trial, 
2 infusions of 0.5 mg/kg of MNL-02 given at 29 days apart were effective 
in attaining response at 6 weeks in moderately active UC. 
SURGICAL   MANAGEMENT 
 Approximately 25% to 35% of UC patients will require surgery for 
their disease. Indications are severe, fulminant, steroid-refractory disease, 
the presence of dysplasia on targeted or random biopsies, and the 
detection of colorectal cancer. The most common surgical intervention 
for UC patients is total proctocolectomy  with either an end-ileostomy or 
with an ileal-pouch anal anastomosis (IPAA). 
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HEALTH  MAINTANANCE 
 Osteopenia and osteoporosis are common problems in UC patients. 
The risk of osteopenia and osteoporosis in UC is estimated to have a 
prevalence as high as 70% (36). Patients with evidence of osteopenia 
should be checked for vitamin D deficiency and treated accordingly. 
Patients with osteoporosis should begin treatment with a bisphosphonate. 
 Nutritional deficiency like iron deficiency due to blood loss and 
chronic inflammation; iron studies  should be checked and repleted. 
Folate and vitamin B12 levels are also important to assess, especially in 
patients with anemia. Sulfasalazine impairs folate absorption, thus 
patients on this drug should receive daily  folate supplementation. 
 Colorectal cancer screening is a part  of management  in UC. Major 
gastroenterological  societies  recommend regular annual surveillance 
with colonoscopy in those who  had pancolonic UC for 8 or more years  
and 12 to 15 years of  left sided colitis after initial diagnosis. 5-ASAs 
may have a role in decreasing the risk of CRC in UC, but further studies 
are needed. 
 A sizable percentage of UC patients have not been immunized 
against vaccine-preventable infections. IBD patients should routinely be 
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vaccinated for the following if they are not yet immune: hepatitis A, 
hepatitis B, influenza, tetanus, streptococcal pneumonia (Pneumococcus), 
diphtheria, pertussis, and varicella. Meningococcus and human papilloma 
virus vaccines should be administered to target populations (adolescents 
and young women, respectively). It is important to administer 
vaccinations prior to the administration of immunomodulators, anti-TNF 
therapy, or steroids. 
 Fertility is decreased for both men and women with IBD. In men, 
ongoing therapy  with immunomodulators (MTX, 6-MP)  fertility rate is 
decreased. 
WHICH IS THE BETTER WAY TO DETERMINE RESPONSE TO 
THERAPY IN UC: SYMPTOMS OR ENDOSCOPIC 
ASSESSMENT? 
 
 In clinical practice, the response to disease activity in UC is 
determined by assessing clinical symptoms such as the presence or 
absence of blood, the number of stools per day, and the presence or 
absence of evidence of systemic toxicity. In addition, to this other means 
such as elevation in the ESR or CRP can be useful in assessing the 
severity of UC.  
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 Mucosal healing is the best ultimate goal, because it is associated 
with long period of remission, steroid sparing and decreases colectomy 
rates. It also decreases dysplasia and colorectal malignancy.  
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AIM  AND OBJECTIVES OF THE STUDY 
1. To evaluate whether the clinlcal  disease severity in ulcerative 
colitis and lab parameters reflect the degree of endoscopic activity. 
2.  To asses whether endoscopic findings during remission  predicts 
the future  clinical disease pattern. 
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MATERIALS AND METHODS 
 This is a pospective study conducted in  the Department of 
digestive health and diseases, Govt. peripheral hospital, Annanagar, 
Kilpauk Medical College, Chennai from April 2012-february 2013. 
INCLUSION CRITERIA: 
 Patients with a  clinical  diagnosis of ulcerative colitis , who 
underwent colonoscopic examination and had  histological   confirmation  
of  ulcerative colitis were included. 
EXCLUSION CRITERIA: 
Infectious enterocolitis 
Colorectal cancer 
Crohn's disease 
Indeterminate colitis 
Pregnancy 
Children 
History of colorectal  operation 
NSAID or intake of aspirin (≥2 tablets/week). 
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 First the study protocol was designed and our institution ethical 
committee approved the design of the study. Then the patients taken for 
this study were explained about the whole  study and an informed consent 
was obtained. 
 The patients who came to our out patient department during the 
study period with a  diagnosis of ulcerative colitis were  included. All the 
particulars of the patients were obtained as per proforma attached here 
with . Patients were interviewed about their demographic  details first. 
Then detailed history about clinical presentation , duration of illness, past 
history, personal and family history, environmental and psychological 
factors prior to the onset of disease were asked. A thorough  clinical 
examination was done.  Complete hemogram, basic blood chemistry, 
liver function test CRP were done as per proforma. The patients  was also 
looked for the presence of extra intestinal manifestations.  Disease 
severity was  assesed using  Truelove and Witts classification and they 
were stratified into mild, moderate and severe disease respectively. 
 Simultaneous Colonoscopic  examination was performed . All the 
patients undergoing colonoscopy were prepared with PEGLEC as per our 
routine hospital protocol. Patients were instructed to be on liquid diet 24 
hours prior to colonoscopy. One packet of  PEGLEC powder mixed with 
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two liters of plain water was asked to drink  in split doses, half in the 
previous day evening and another half in the morning. Patients were 
allowed to take only clean liquid following that. 
 Colonoscopy was done in the morning. Colonoscopy was done 
with PENTAX video colonoscope . Endoscopic assessment and grading 
was done for all patients who underwent colonoscopy (Baren et al). 
Biopies were taken as required and sent to our pathologist for tissue 
diagnosis. 
 Diagnosis of UC was made by combination of clinical, endoscopic 
appearance and histopathological examination. Only histopathologically 
confirmed cases from our hospital during the study  period were taken for 
this study. 
 Baseline clinical severity, laboratory parameters and endoscopic  
grading  were recorded for all these patients. These patients were treated 
as per the  standard treatment protocol . These patients were in follow up 
and looked for clinical response.  
 Clinical remission  was reflected by a  normal frequency of bowel 
movements and no bleeding per rectum. Once the patient was in clinical 
remission  and compliant with therapy ,they were all subjected to a repeat 
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colonoscopic examination at 3 and 6 months respectievely  and the 
treatment  response was assesed  based on  mucosal healing  (Baron et al 
: 0-normal, 1-granular oedematous mucosa with absence of vascular 
pattern, 2-bleeds on  touch, 3-spontaneous bleed). Lab parameters were 
also done during this time. Analysis  was done to find   the  correlation 
between  clinical severity  and endoscopic   activity of the disease at  
remission. 
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STATISTICAL ANALYSIS 
 While studying the relation between  test results, clinical severity 
and endoscopic grading ,the chi square test or Fishers exact  test was used 
when appropriate, and a multivariate analysis was performed using a 
logistic regression analysis. Significance was assigned to any probability 
value of  less than 0.05. 
 The statistical software package SPSS for windows version  (SPSS 
Inc, Chicago III) was used to analyse the data. Mean and standard 
deviations were used to summarize data for continous variables whereas 
percentages were used for categorical variables. 
 
 
 
 
 
.  
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RESULTS 
 In this study 14428 patients attended our OPD as new cases. Out of 
which 158 had bleeding per rectum and diarrhea. 101 patients had history 
and clinical features suggestive of Inflammatory bowel disease were  
included. All patients who gave consent under went  laboratory 
examination and  colonoscopic examination. 48  patients were excluded 
due to various reasons like 
Not given concent for colonoscopy   2 
Histology Tuberculosis     3 
Histology non specific colitis    22 
Cronhs disease      2 
Infective colitis      2 
Ischemic    colitis      1 
Not  willing  for follow up colonoscopy  12 
Poor   compliance  & not in remission   4 
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DEMOGRAPHIC DETAILS 
Table 1 Demographic profile 
AGE Numbers % 
<20     yrs 1 2 
21-30 yrs 16 30 
31-40 yrs 15 27 
41-50 yrs 11 21 
51-60 yrs 8 14 
>60    yrs 3 6 
 
 Among the  53 patients 30 were male and  23 patients were female. 
Sex ratio was 1.3:1. Age ranges  from  16  to  64  years. 36 year was the  
mean age .   Peak  age at which disease onset was noted   was in the  third  
decade. All the patients were from the geographical location around north 
Tamilnadu. 95% of them belongs to low socioeconomic group. 
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DURATION OF  SYMPTOMS 
Table 2 Duration of symptoms 
 
 
 
 
 
 The average period of symptoms prior coming to the hospital 
ranges  from 15 days to 5 years. 73.6% had disease duration less than  
6 months. 
RISK FACTORS 
 Using the questionnaire the risk factors were analyzed. One patient 
had family history of IBD. In this study 6% were previous smokers. 4% 
had history of NSAID intake. None of them had previous history of 
appendisectomy. None was on oral contraceptive pills. 
DURATION NUMBER % 
<6 MONTHS 39 73.6 
6 MONTHS-2 YRS 10 18.9 
2-5 YRS 4 7.5 
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CLINICAL PRESENTATION 
 The commonest clinical presentation  was diarrhea, but nocturnal 
symptom was present in 32%.  Rectal bleeding  was present in 69.8% of 
cases. 9.4% had fever. Pain abdomen , tenesmus, urgency were other 
features. 
CLINICAL ASSESMENT OF SEVERITY-TRUELOVE AND 
WITTS CLASSIFICATION          
TABLE 3:CLINICAL SEVERITY OF DISEASE 
 
 
 
 
 
 
 According to Truelove and Witts classification ,mild  disease was 
commonly encounted  in this study (58.5% ). 22.6% had moderate 
disease. Severe disease was present in 18.9%. 
TRUELOVE AND WITTS NUMBER % 
MILD 31 58.5 
MODERATE 12 22.6 
SEVERE 10 18.9 
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LABORATORY FINDINGS 
TABLE 4:BASELINE LAB PARAMETERS 
 N Minimum Maximum Mean Std. Deviation
Albumin         
(gm/dl) 
53 2.2 4.2 3.30 1.194 
Platelet count 
(lakhs) 
53 1.5 4.6 2.515 1.2922 
ESR 
(mm) 
53 7 98 31.77 23.352 
HB 
(gm %) 
53 6.0 14.3 10.443 1.7455 
CRP 
(mg/dl) 
53 2 98 13.42 18.496 
TC                     
(cmm) 
53 1200 12900 8057.4 2324.598 
 
CORRELATION OF DISEASE   ACTIVITY WITH CLINICAL & 
LABORATORY PARAMETER 
 Nocturnal diarrhoe (P=.01)   and   fever (P=.03) had a positive 
correlation  with  clinical severe disease activity.CRP is a marker of 
active disease.(P=.000). 
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TABLE 5:CLINICAL ACTIVITY  & LAB PARAMETERS 
VARIABLES Mild Moderate Severe P value 
TC 21/31 3/12 3/10 .065 
HB 20/31 10/12 6/10 .070 
ESR 7/31 4/12 4/10 .061 
CRP 2/31 7/12 8/10 .000 
ALBUMIN 7/31 3/12 1/12 .072 
PLATLETS 4/31 1/12 3/10 .082 
NOCTURNAL DIARRHOEA 5/31 5/12 7/10 .01 
RECTAL BLEEDING 31/31 4/12 2/10 .062 
FEVER 0/31 0/12 5/10 .03 
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ENDOSCOPIC  DISTRIBUTATION  OF DISEASE 
At  initial presentation ,the endoscopic pattern was 
Proctitis 35.8% 
Proctosigmoiditis 26.4% 
Left sided colitis  13.2% 
Extensive colitis 5.6% 
Pancolitis 18.9% 
 Proctitis was the commonest presentation in this study. None of the 
patients had  acute fulminant colitis. 
ENDOSCOPIC DISTRIBUTATION AND    CORRELATION OF 
CLINICAL  &  LAB  PARAMETERS 
 Tenesmus and urgency were   associated with proctitis and 
proctosigmoiditis. Presence of fever  had a positive correlation with 
pancolitis. Laboratory variables when  correlated with disease 
distribution, CRP correlated  well with proximal distribution of disease 
CRP  (P=.001) 
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CLINICAL SEVERITY AND ENDOSCOPIC DISTRIBUTION OF 
DISEASE 
 Distal colon is involved if the patient had a mild clinical activity.   
Extensive colitis and pancolitis  were  associated with severe disease 
activity. 
TABLE 6:CLINICAL & ENDOSCOPIC CORRELATION 
Trueiove 
& witts 
Proctitis Procto 
Sigmoiditis 
Left 
sided 
colitis 
Extensive 
colitis 
Pancolitis
Mild 17 14 1 0 0 
Moderate 2 0 5 0 3 
Severe 0 0 1 3 7 
Total 19 14 7 3 10 
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 Value Df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 63.692(a) 8 .000 
Likelihood Ratio 64.304 8 .000 
Linear-by-Linear 
Association 
37.457 1 .000 
N of Valid Cases 53   
 
EXTRAINTESTINAL MANIFESTATIONS 
 15 % had extra intestinal manifestation in this study. Vascular 
thrombosis, axial & peripheral arthropathy and uveitis  were the 
manifestations. None of them had neither cutaneous  lesion nor primary 
sclerosing cholangitis. 
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TABLE 7: EXTRAINTESTINAL MANIFESTATIONS 
SYSTEM   INVOLVED PRESENT % 
RHEUMATOLOGY 3 6 
OPTHAL 2 4 
CUTANEOUS 0 0 
HEPATOBILIARY 0 0 
VASCULAR 3 6 
 
TREATMENT GIVEN TO THE PATIENT 
 36 patients(67.9%) were treated with sulphasalazine,14 (26.4%) 
were treated with  sulphasalazine  and  prednisolone and 3(5.6%)  with 
azathioprine  and prednisolone respectievely. Biologicals were not used. 
All had clinical remission in this study. 
CLINICAL VS ENDOSCOPIC REMISSION FOLLOWING 
TREATMENT 
 36 patients with mild to moderate disease  were treated with 
sulphasalazine in the dose of 4 gms per day. Colonoscopy was done at 
three months  and six  month, while the patients were continuously taking  
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sulphasalazine therapy. During this time all of them were in clinical 
remission. The endoscopic findings at 3 & 6 months were  compared with 
the baseline colonoscopic findings. 
SULPHASALAZINE THERAPY AND MUCOSAL HEALING  
 No mucosal healing was noted in 80.5% and 70.5% at 3 and  
6 months. A  partial mucosal response was noted in19.5% and 25% 
respectievely  at three and six months.  Sulphasalazine therapy was not 
associated with a complete mucosal healing in this study. 
TABLE :8   ENDOSCOPIC RESPONSE  & SULPHASALAZINE 
THERAPY 
DURATION PARTIAL COMPLETE TOTAL 
RESPONSE 
NO 
RESPONSE
3 MONTHS 7 0 7/36 
19.5% 
29/36 
80.5% 
6 MONTHS 9 0 9/36 
25% 
27/36 
75% 
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MUCOSAL HEALING IN SULPHASALAZINE AND 
PREDNISOLONE GROUP 
 Fourteen were treated with sulphasalazine, four gms per day and 
oral prednisolone 40 mgs / day for 4 -  6 weeks, followed by decreasing 
the dose  of prednisolone. Colonoscopy at three months , response was 
noted  in 21.4%.All of them had a partial response only. 
 They were followed at 6 months both clinically and 
endoscopically. All of them were in clinical remission but 42.9% had an 
endoscopic response. Also 40% had a distal shift in distribution of 
disease. 
TABLE :9  ENDOSCOPIC RESPONSE  IN  SULPHASALAZINE 
WITH PREDNISOLONE 
DURATION PARTIAL COMPLETE TOTAL 
RESPONSE 
NO 
RESPONSE 
3 months 3 0 3/14  21.4% 11/14 
6 months 5 1 5/14  42.9% 8/14 
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ENDOSCOPIC RESPONSE IN AZATHIOPRINE & 
PREDNISOLONE GROUP 
 6 of them was initially in this group .Because of the intolerance to 
drug, 3 of them moved to the other group. In   this group, complete, 
partial and nil response was observed in 33%  each respectievely, both at 
three and six months. 
ROLE OF LABORATORY PARAMETERS DURING THE 
FOLLOW UP PERIOD 
 All the lab parameters were also repeated during the follow up 
period. But no correlation was noted  between ESR, CRP with the clinical 
disease activity during the third and sixth months. During which time, 
even though all  the patients were in clinical remission. they haven’t 
attained endoscopic healing. 
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T-Test 
TABLE :10  Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 CRP 1&
53 .694 .060 
 CRP 2    
Pair 2 CRP 1&
CRP3 53 .445 .017 
 
COMPLICATIONS 
Skin rash  2 
Anemia  4 
Obesity  3 
 Exacerbation of symptoms following endoscopy were seen in 4 
patients. 
 No major adverse reactions were  encountered during  the study 
period. 
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DISCUSSION 
 Ulcerative colitis is a common disease in most of the industrialized 
countries in the world, but it was thought to be uncommon in the 
developing countries (37). The highest incidence is reported from 
Scandinavia and Scotland  and then by England and North America (38). 
In the West, the incidence and prevalence of UC is  8–14 per 100,000 and 
120 -200 per100,000 persons, respectively (39). 
 Limited community studies were available from India. One 
community study from Punjab reveals the incidence of UC was 
6.02/100000 per year and a prevalence rate of 44.3/100000 
population.(40) but  several hospital incidence  rates were available from 
India and it was 12/10,000 by  Sood et al 1999. 
 But in this study the hospital incidence of UC was 36/10000. An 
increasing trend  was noted  The temporal association of the  increasing 
incidence rates  is  related to the change in westernisation of lifestyles, 
change in diet as well as in the  environment caused by  industrialization 
and urbanization (41). 
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 Age ranges from 16 -64 years and the mean age was 36 years in 
this study. The maximum number of patients were in the  third decade.  
Following  were the various studies on UC, from India 
Author                            Mean (yrs)                 Range (yrs) 
Sood et al  Ludhiana                   31.7                                  14-65 
Khosla et al Rohtak           24.4 (M)  38.0 (F)                           
Kapur P et al Delhi         13-65 
Kochhar et al  PGI                                                     13-78 
Chuttani et al  MAMC    31.5 (M), 25.3 ( F)       9-56 
 Patients in India present mostly  in 3rd and 4th decade and  failed to 
show a bimodal age  pattern (42). But in the West  a bimodal  distribution 
was noted  characterized by a small late surge in the elderly, between  
60 and 70 years.(43). 
 Males were affected slightly more than females, the ratio being 
1.3:1. Another study by Tandon  et al ,Delhi ,the sex ratio was  1.5:1. 
Most studies  from West  did not  showed  any difference  among gender 
in the occurrence of UC. The  male-to-female ratio of  about 1 : 1  was 
found in all age groups.(44). 
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 In this study, the average duration of symptoms prior coming to the 
hospital ranges  from 15 days to 5 years. 73.6% had disease duration less 
than 6 months. Similar result was observed in a North Indian study and 
the mean duration of symptoms before coming to hospital entry was  
2.7 years. 
 Association of IBD among  family, occurs in first-degree relatives 
The relative risk of UC in a sibling was estimated to be around 7% and 
17% based on western studies .Here also 1 patient (1.8%) had family 
history of IBD. 
CLINICAL ASSESMENT OF SEVERITY-TRUELOVE AND 
WITTS CLASSIFICATION 
 
 On the basis of Truelove and Witts  classification majority had  
mild disease (58.5%) at presentation. Moderate and severe disease were 
noted in 22.6% & 18.9%  respectievely . A recent review report  says  
that  ulcerative colitis in India runs a mild course (45). The disease course 
reported in Indian immigrants in England and Durban was mild to 
moderate on clinical presentation (46).  In the West there was a variance 
in the severity of disease  reported in epidemiological studies and hospital 
based studies. 
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ENDOSCOPIC DISEASE ACTIVITY 
 At initial presentation 35.8% had proctitis and 26.4% had 
proctosigmoiditis. Distal disease was commonly noted in this study. Left 
sided colitis and extensive colitis were observed in 13.2% & 5.7% 
respectievely. Pancolitis was present in 18.9%. In  a study from India half 
of the patients had left sided colitis (47.5%), proctosigmoiditis in 25% 
and pancolitis in 27.5%. 
 In one of the latest reviews from the West (47), 46% had 
proctosigmoiditis, 17% left sided colitis and 37% had pancolitis. 
According to a prospective, Norwegian study,(48) at  initial presentation, 
proctitis was present  in 1/3 rd of patients, another one-third had left sided 
colitis,  in the remaining third  there was proximal extension beyond the 
splenic flexure. Pancolitis was seen  in 25% of the patients. 
 The distribution of the disease varies according to age, ethnicity 
and risk factors.  A recent publication from Japan described that mild 
colitis and proctitis were    significantly larger in patients who had onset 
of disease  at older than 60 years, relatively  to those who experienced 
onset at younger than 30 years (P<.016).(49). 
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CLINICAL PRESENTATION & ENCOSCOPIC DISEASE 
ACTIVITY 
 Diarrhoea and rectal bleeding were the commonest clinical 
presentation. Nocturnal diarrhea and fever had a positive correlation  with 
the  endoscopic severity of the disease. They had  either extensive  colitis  
or pancolitis.  Kato and colleagues confirmed  that severe clinical activity 
was seen more commonly in patients who had severe disease activity in 
the proximal colon compared with the rectum or sigmoid  (50). 
 In this study, rectal bleeding and urgency were associated with 
distal colonoscopic lesion. Similar result was seen in another study from 
Tokyo (51). 
LAB PARAMETERS & SEVERITY OF DISEASE 
 In this study patients with elevated CRP  had either pancolitis or 
extensive colitis. It  had a positive correlation   with the severity of the 
disease. Similar result was seen  in  another study from Rochester.(52)  In 
another Japanese study  ,CRP elevation reflects  the activity of proximal 
lesions. 
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ENDOSCOPIC ASSESSMENT OF RESPONSE TO TREATMENT 
 Sulfasalazine is a  5-ASA compound , used as first line  therapy for 
the  induction of  remission in patients with mild to moderate UC.   In this 
study, sulphasalazine therapy in mild to moderate disease had  100% 
clinical remission ,but  not associated with a significant endoscopic   
response.  No mucosal healing was   seen  in 80.5% and 75% at 3 and  
6 months. Only  a  partial mucosal response was noted in19.5% and 25% 
respectievely  at three and six months.  Sulphasalazine therapy was not 
associated with a complete mucosal healing in this study. 
 In another study, sulfasalazine ,3 to 6 g/day induces remission in 
39% to 62%  with mild to moderate UC. A dose-dependent response  was 
reported when it was used for  induction  in active UC.(43).  In the 
ASCEND I &II  trials, mesalamine  at 2.4 & 4.8 gm per day  in mild 
disease had similar efficacy, but in moderate active disease a higher 
dose(4,8 gm) was more effective  to  induce mucosal healing. This dose 
of mesalamine is comparable to 12 grams of sulphasalszine. 
 Recent studies have concluded that  improved release formulations   
of  5 ASA & more aggressive dosing schedules were needed for inducing 
remission in UC.   Dosages of mesalamine of less than 2.0 g/d are 
ineffective for inducing remission. 
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 The poor response to sulphasalazine in this study can be attributed 
to   the  lower dose  4 grams per day, used in this study. 
 In case of sulphasalazine  and  prednisolone combination therapy,    
mucosal healing  was  seen in  21.4% & 42.9 % respectievely at 3 and  
6  months in this study. The long-term remission rate  in patients  on 
glucocorticoids for severe UC is reported as approximately 50% (43). 
 Another report says, with corticosteroids, 54% achieved complete 
remission, 30% partial response, and 16% no response over first  
30 days. (53). 
 In AZA  and prednisolone group, mucosal healing was  found in 66 
%.No response was seen in 33%. One randomised controlled trial showed 
that  azathioprine along with glucocorticoids  had a response rate of 79%  
at one month. A varying result was given by another trial, the response 
rate was 53% at six months. 
 Rutgeerts  et al ,in his study  Infliximab produces  mucosal healing 
in about  50% of patients at 30 weeks. 
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 Kohn et al ,in  a small series reported that 77% clinical response 
was seen  after a single infliximab infusion of 5 mg/kg, & 80% of the 
responders were  in clinical remission after a period of  2 years. 
ROLE OF CRP AND MUCOSAL HEALING 
 In this study, CRP  that was done subsequently at 3 & 6 months   
while the patients were in clinical remission doesn’t correlate with the 
clinical activity. This might be because  of the presence of endoscopic 
disease activity. Solern et al,in his study  elevated CRP is a marker of 
endoscopic activity.(52) 
COMPLICATIONS 
 No major complications were encounted during this study. Recent 
data from IBSEN study with 10-year follow-up also did not observe a 
significant increased risk of death in patients with UC.(55) 
 Mild exacerbation of clinical symptoms were noted following 
colonoscopy in 4 patients.  Recent colonoscopy is associated with a flare 
in UC.(56) 
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CONCLUSION 
1. This study fails to show a bimodal age distribution in UC. 
2.  On the basis of Truelove and Witts  classification majority had  a 
mild  disease. 
3. Proctitis was the commonest colonoscopic finding in this study. 
4. Mild  clinical disease was associated with distal colitis and   severe 
disease  was found to have either extensive or pancolitis. 
5. Nocturnal diarrhea  and fever were observed more commonly  in 
patients who had maximum disease activity in the proximal colon 
compared with the rectum or sigmoid. 
6. CRP elevation reflects  the activity of proximal lesions . 
7. In patients with mild to moderate disease none of the patients had a 
complete  mucosal healing  response   with sulphasalazine therapy 
at 3 and 6 months  respectievely .Sulphasalazine 4 grams  may be a 
suboptimal dose. 
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8. Elevated CRP during the follow up period ,while the patient is in 
clinical remission indicates  the  absence of mucosal healing. This 
can be used as an indirect marker to predict future response. 
9. Full colonoscopy is particularly important in the initial mapping of 
disease extent and severity as well as to investigate any 
discrepancy between clinical symptoms and endoscopic 
appearance. 
10. Mucosal healing as assessed by endoscopy is a useful tool for 
evaluating and guiding response to therapy in patients with IBD. 
11. Mucosal healing is an admirable goal that we should strive to 
achieve in  each of our patient on a regular basis. 
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LIMITATIONS OF THIS STUDY 
1. Dose of sulphasalazine  is probably short of therapeutic range  in 
moderate  UC. 
2. Sample size were small in steroid and azathioprine group. 
3. Biologicals were not used. 
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ANNEXURE – A  
PROFORMA 
 
NAME                                         AGE                                                     SEX: 
DDHD  NO:                                 DIAGNOSIS:                                      DURATION: 
 
EPIDEMIOLOGY                         Drug 
Place Skin/Eye problem 
Per capita income CAD 
COMPLAINTS PAST HISTORY 
Pain abdomen DM 
Loose stools HTN 
Nocturnal symptoms Surgery 
Blood in stools FAMILY HISTORY 
Fever IBD 
Fatigue, tiredness PERSONAL HISTORY 
Weight loss Smoker 
Jaundice Alcahol abuse 
Joint pain Tabacco 
 
 
 
 
 
GENERAL EXAMINATION INVESTIGATIONS 
BMI HB 
Temperature TC 
Pulse DC 
BP ESR 
Pallor PLATELET 
Skin lesions ALBUMIN 
Jaundice RFT 
Eyes CRP 
Oral cavity STOOL 
Joints TRUELOVE &WITTS 
Peripheral vessels Mild 
ABDOMEN Moderate 
RECTAL Severe 
 
 
 Baseline(1) 3 months (2) 6 months (3) 
COLONOSCOPY    
ESR    
CRP    
HB    
TC/DC    
PLATELET    
 
                                              
 
ANNEXURE – B  
MASTER CHART 
No Age sex 
dura-
tion 
diar-
rhoea 
rectal 
bleed fever platelet 
ESR 
1 HB1 
CRP 
1 
true 
luv 
colon 
1 
colon 
2 TC 
HB 
2 ESR2 CRP2 
ESR 
3 
CRP 
3 
colon 
3 extra treatment 
1 54 m 2 4 2 0 1.5 7 11.7 6 S1 P1 P1 6500 11.9 8 7 7 5 P1 nil S 
2 60 f 3 3 3 0 2.3 10 11 2 S1 P2 P2 5342 10.8 12 8 10 4 P1 nil S 
3 30 f 3 4 1 0 1.8 11 10.8 8 S1 P1 P1 7800 11 11 8 8 6 P1 nil S 
4 63 f 0.5 6 2 0 1.9 30 8.7 11 S2 P2 P2 9100 8.5 10 5 16 17 P2 nil S 
5 47 m 2 4 4 0 2.4 120 6.6 13 S1 P2 P2 7600 9.5 37 7 11 3 P2 nil S 
6 25 f 3 4 4 0 4.8 60 9.3 24 S1 L2 L2 8240 10 28 11 12 6 L2 DVT S 
7 60 f 3 4 3 0 1.9 20 12 5 S1 PS1 PS1 7600 11.8 12 6 21 3 PS1 nil S 
8 30 m 1 5 4 0 1.6 23 11 7 S1 PS2 PS1 7333 11.7 10 3 11 5 PS1 nil S 
9 42 m 2 15 12 0 1.9 97 11.8 13 S3 PA3 PA1 8900 12.8 34 7 22 8 PS3 nil SP 
10 38 m 12 4 3 0 2.6 12 14.3 3 S1 P2 P2 7600 11.8 7 5 21 4 P2 nil S 
11 38 f 48 4 4 0 2.8 13 12.5 8 S1 P1 P1 8110 12.9 10 4 22 11 P1 nil S 
12 64 m 0.25 4 2 0 1.7 11 13.2 4 S1 PS2 PS2 6500 13 8 6 6 5 PS2 nil S 
13 22 m 24 10 10 0 2.8 28 10.3 98 S3 PA3 L3 9100 12 16 17 11 5 PS2 nil SP 
14 42 f 4 4 3 0 3 21 11 5 S1 P1 P1 7600 11.8 11 3 8 3 P1 nil S 
15 54 f 3 4 3 0 1.9 12 12.9 6 S1 PS2 PS2 9300 12 12 6 5 5 PS2 nil S 
16 31 m 3 4 4 0 3.1 39 10 5 S2 PA2 E3 8000 11.3 21 3 6 5 P2 nil SP 
17 16 m 4 12 2 0 2.1 11 14 3 S2 P2 P2 6200 13.8 11 5 6 6 P2 nil S 
19 22 m 6 4 3 0 2.3 52 8 5 S1 PS1 PS1 6720 9 22 8 11 12 PS1 nil S 
10 22 m 3 0 3 0 2.7 12 10 8 S1 P1 P1 5880 11.2 21 4 9 9 P1 nil S 
20 38 m 24 5 3 0 2.6 23 11 4 S1 PS2 PS2 7600 12 22 11 14 4 PS2 nil S 
21 42 m 1 14 12 1 2.2 43 10.7 76 S3 PA2 E2 8400 11.8 6 5 11 6 E1 nil SP 
22 36 m 3 4 3 0 2 17 11.3 5 S1 P2 P2 6500 11.8 11 5 21 5 P2 nil S 
23 54 m 2 8 8 1 3.6 30 10.4 55 S3 E2 E1 4800 11 8 3 9 8 E1 nil SP 
24 30 m 6 7 6 0 1.8 34 12 13 S2 PA2 PA2 9320 11 5 5 18 6 PA2 nil SP 
25 35 m 0.5 4 3 0 1.6 12 11.4 7 S1 P2 P2 7600 10.6 6 5 11 3 P2 nil S 
26 20 f 6 4 3 0 1.5 21 12 5 S1 P2 P2 5700 11 6 6 10 5 P2 nil S 
27 57 f 2 10 9 0 1.8 54 7.9 17 S3 PA2 PA2 9800 8.5 11 12 37 7 PA2 nil SP 
28 28 f 36 15 12 1 1.9 43 6 43 S3 PA3 PA3 11900 9.8 9 9 28 11 PS1 nil SP 
No Age sex 
dura-
tion 
diar-
rhoea 
rectal 
bleed fever platelet 
ESR 
1 HB1 
CRP 
1 
true 
luv 
colon 
1 
colon 
2 TC 
HB 
2 ESR2 CRP2 
ESR 
3 
CRP 
3 
colon 
3 extra treatment 
29 52 f 18 0 3 0 2 13 11 4 S1 PS3 PS3 7690 11 14 4 12 6 PS3 nil S 
30 55 m 12 4 4 0 2.8 17 10.7 4 S1 PS2 PS2 3560 11.9 11 6 10 3 PS2 nil S 
31 60 f 3 3 2 0 3 10 12 6 S1 PS2 PS2 6700 11 21 5 34 7 PS2 nil S 
32 33 m 12 0 2 0 1.8 23 8.6 16 S1 P2 P2 12000 9.7 9 8 7 5 P2 nil SP 
33 41 f 6 7 6 0 4.5 83 9.6 23 S3 E2 E2 12400 10.6 18 6 10 4 E2 nil S 
34 28 m 3 4 4 0 1.6 12 11,8 5 S1 P2 P2 1200 11.7 11 3 8 6 P2 nil S 
35 45 m 12 0 4 0 1.9 23 12 7 S1 PS2 PS2 7800 11.9 8 3 16 17 PS2 nil S 
36 37 m 6 4 3 0 1.7 21 11 5 S1 P2 P2 6500 12 16 4 11 3 P2 nil S 
37 22 m 4 7 6 0 1.6 43 7.8 12 S2 L3 L3 9700 9.7 35 7 12 6 L3 E S 
38 32 f 24 4 4 0 3.6 23 9.8 8 S2 PS3 PS3 6890 10.7 12 5 21 3 PS3 nil S 
39 36 m 3 12 8 0 3.2 34 9.7 8 S2 L2 L2 6500 10.8 22 3 11 5 L2 nil S 
40 38 m 12 4 4 0 3.7 12 10 5 S1 P2 P2 8900 11 11 6 22 8 P2 nil S 
41 28 f 24 20 15 1 3.4 32 7.9 12 S3 E2 PS2 5800 9.6 19 7 21 4 PS2 nil SP 
42 45 f 7 0 3 0 2.3 40 12.3 6 S1 PS2 PS2 4560 12 11 4 22 11 PS2 nil S 
43 40 m 2 8 6 0 2.6 45 10.5 6 S2 PA3 P2 10700 11 12 7 6 5 P2 nil AP 
44 21 f 6 6 6 0 9.6 23 11 7 S2 L2 L2 9200 11 12 4 11 5 L2 DVT S 
45 41 f 4 7 4 0 1.8 82 9.2 10 S2 L3 PS 12700 10 40 7 8 3 P2 nil AP 
46 38 m 6 7 6 0 1.9 34 9.4 9 S2 L2 L2 8200 10.2 15 3 5 5 PS1 nil SP 
47 31 f 60 4 4 0 2.4 25 9.8 5 S1 PS3 PS3 10700 10 17 7 6 5 PS3 nil S 
48 28 f 3 15 12 0 4.9 23 9.7 12 S3 PA2 PS2 12900 11 21 7 6 6 E3 DVT SP 
49 25 m 12 15 6 1 1.8 64 7.3 54 S3 PA2 PA2 11700 8.9 34 10 11 12 PA2 R AP 
50 36 m 4 8 6 0 1.8 43 9.4 12 S2 L2 L2 8200 10 21 7 9 9 L2 nil S 
51 43 f 24 8 nil 0 1.9 40 12.4 5 S1 PS2 PS2 11200 11 21 3 14 4 PS2 nil S 
52 34 m 3 4 4 0 1.6 21 9.8 4 S1 P2 P2 7800 11 12 5 11 6 P2 nil S 
53 28 f 7 4 3 0 1.8 32 11 7 S1 P2 P2 8500 10.7 17 2 21 5 P2 nil S 
 
 
